Virchows Archiv

, Volume 456, Issue 5, pp 515–521 | Cite as

Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas

  • Özgür Mete
  • Yersu Kapran
  • Mine G. Güllüoğlu
  • Işın Kılıçaslan
  • Yeşim Erbil
  • Yasemin Giles Şenyürek
  • Ferhunde Dizdaroğlu
Original Article


In the evaluation of retroperitoneal masses, the practicing pathologist faces a dilemma when making a diagnosis based on histology given the often overlapping morphologic appearances of the adrenocortical carcinoma, renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC). CD10 is expressed in a membranous fashion in the vast majority of clear cell RCCs; therefore, it is widely used for distinction from its mimics. However, its expression is not well-investigated in adrenal cortical tumors. We examined CD10 expression in 47 surgically resected adrenocortical tumors (26 adenomas and 21 carcinomas) and compared with 20 clear cell RCCs and 25 HCCs. Twenty HCCs (80%), 18 RCCs (90%), 11 adrenocortical carcinomas (52%), and 18 adrenocortical adenomas (69%) were positive for CD10. HCCs were characterized by a canalicular staining, and clear cell RCCs exhibited membranous or mixed membranous-cytoplasmic staining. Adrenocortical tumors displayed mainly cytoplasmic staining. Four adrenocortical carcinomas and one adenoma also displayed the membranous staining pattern. Despite the relatively small number of samples, our preliminary results revealed that adrenocortical tumors may express CD10 (Clone: 56C6). The most important point from this paper is the fact that anti-CD10 expression has not been previously reported in adrenocortical carcinomas. This suggests that CD10 does not seem to be a useful marker for discriminating clear cell RCCs from adrenocortical tumors since CD10 expression does not rule out the possibility of adrenocortical tumors. This feature should be kept in mind when constructing an antibody panel for an epithelial tumor that involves the adrenal gland and kidney, especially in small biopsy specimens.


CD10 Adrenocortical carcinoma Adrenocortical adenoma Hepatocellular carcinoma Renal cell carcinoma 



This study was supported by the research fund of Istanbul University (Project number: UDP-2768/23072008). The preliminary results of this study were partially presented during the poster session of the XXVII. Congress of the International Academy of Pathology in Athens (October, 12–17, 2008).

Conflict of interest statement

We declare that we have no conflict of interest.


  1. 1.
    McIntosh GG, Lodge AJ, Watson P et al (1999) NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 154:77–82PubMedGoogle Scholar
  2. 2.
    Chu P, Arber DA (2000) Paraffin-section detection of CD10 in 505 non-hematopoietic neoplasms: frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol 113:373–382Google Scholar
  3. 3.
    Langner C, Ratschek M, Rehak P et al (2004) CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathol 45:460–467CrossRefGoogle Scholar
  4. 4.
    Avery AK, Beckstead J, Renshaw AA et al (2000) Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 24:203–210CrossRefPubMedGoogle Scholar
  5. 5.
    Pan CC, Chen PC, Tsay SH et al (2005) Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 13:347–352CrossRefPubMedGoogle Scholar
  6. 6.
    Mete O, Kilicaslan I, Uysal V (2009) Does CD10 immunoexpression have a diagnostic utility in the differential diagnosis of renal oncocytomas and eosinophilic variants of chromophobe renal cell carcinomas? Pathol 41:191–193CrossRefGoogle Scholar
  7. 7.
    Pan CC, Chen PCH, Ho DMT (2004) The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathol 45:452–459CrossRefGoogle Scholar
  8. 8.
    Kato I, Inayama Y, Yamanaka S et al (2009) Epithelioid angiomyolipoma of the kidney. Pathol Int 59:38–43CrossRefPubMedGoogle Scholar
  9. 9.
    Papandreou CN, Nanus DM (2010) Is methylation the key to CD10 loss? J Pediatr Hematol Oncol 32:2–3CrossRefPubMedGoogle Scholar
  10. 10.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC, LyonGoogle Scholar
  11. 11.
    Stewart CJ, Nandini CL, Richmond JA (2000) Value of A103 (Melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol 53:206–211CrossRefPubMedGoogle Scholar
  12. 12.
    Aydin H, Magi-Galluzzi C, Lane BR et al (2009) Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol 33:289–297CrossRefPubMedGoogle Scholar
  13. 13.
    Zamecnik M, Michal M, Mukensnabl P (2003) Reactivity of granular cell tumors for inhibin and other markers of sex cord and steroid cell differentiation. Am J Surg Pathol 27:413–414CrossRefPubMedGoogle Scholar
  14. 14.
    Schraith DF, Hahm GK, Niemann TH et al (2003) Alpha-inhibin immunoreactivity in soft-tissue neoplasia. Mod Pathol 16:1205–1209CrossRefPubMedGoogle Scholar
  15. 15.
    Banerjee SS, Eyden B (2008) Divergent differentiation in malignant melanomas: a review. Histopathol 52:119–129Google Scholar
  16. 16.
    Doghman M, Cazareth J, Douguet D et al (2009) Inhibition of adrenocortical carcinoma cells proliferation by SF-1 inverse agonists. J Clin Endocrinol Metab 94:2178–2183CrossRefPubMedGoogle Scholar
  17. 17.
    Bakke M, Zhao L, Hanley NA et al (2001) SF-1: a critical mediator of steroidogenesis. Mol Cell Endocrinol 171:5–7CrossRefPubMedGoogle Scholar
  18. 18.
    Kaneko T, Kojima Y, Umemoto Y et al (2008) Usefulness of transcription factors Ad4BP/SF-1 and DAX-1 as immunohistologic markers for diagnosis of advanced adrenocortical carcinoma. Horm Res 70:294–299CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Özgür Mete
    • 1
  • Yersu Kapran
    • 1
  • Mine G. Güllüoğlu
    • 1
  • Işın Kılıçaslan
    • 1
  • Yeşim Erbil
    • 2
  • Yasemin Giles Şenyürek
    • 2
  • Ferhunde Dizdaroğlu
    • 1
  1. 1.Department of Pathology, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey
  2. 2.Department of General Surgery, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey

Personalised recommendations